Slide 1: Dexcom earnings
bpexcom ; y l a Nt if iu ai Dexcom earnings | dees
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains "forward" looking statements that are based on our management's beliefs and assumptions and on information currently available to management as of February 8, 2024. We intend for such forward-looking statements to be covered by the safe harbor provisi
Slide 3: Fourth quarter 2023
Fourth quarter 2023 idl @ © Strong growth with Key Financial Strategic $1.035 billion in revenue Highlights Highlights 26% organic revenue growth! Generated nearly 500 basis points | Submitted Stelo and direct-to-watch (27% US; 23% OUS?) of operating expense leverage feature to the FDA for review co
Slide 4: Fourth quarter performance
Fourth quarter performance Total Revenue & Organic Growth Rate! Non-GAAP Gross Profit and % Margin* ($m) ($MM) $1,200 $1,035 $750 630 $664 $1,000 | $815 ya $871 $975 sooo | $544 sa70 $553 $ $800 $450 Soo $300 $200 +19% +26% +26% +26% $150 63.4% 63.5% 64.7% 64.2% $0 $0 Q4'22 Q123 Q2'23 Q3'23 Q4'23 Q4
Slide 5: 2024 Guidance as of February 8, 2024
2024 Guidance as of February 8, 2024 2024 Annual Revenue and Profitability Guidance Non-GAAP. Non-GAAP Adjusted . . Revenue Gross Profit Margin Operating Margin EBITDA Margin* Key Considerations * Ongoing conversion of Gé to G7 within customer base USD + Extending momentum of = ~ _ 9 ~ 9 ~ 9 2023 la
Slide 6: Appendix
bexcom Appendix Revenue Data and GAAP Reconciliations
Slide 7: GAAP to non-GAAP reconciliations
Three Months Ended December 31, Three Months Ended December 31, (In millions) 2023 2022 (In millions, except per share data) 2023 2022 GAAP gross profit $ 656.6 $ 541.3 GAAP net income $ 256.3 $ 91.8 Amortization of intangible assets (1) 7.2 2.4 Amortization of intangible assets (1) 10.1 4.2 Non-GAA
Slide 8: Revenue Metrics By Component
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 FY'21 FY'22 FY'23 Revenue Metrics By Component Sensor & Other Revenue (millions) (1) (2) $ 424.3 $ 494.5 $ 547.9 $ 598.6 $ 543.2 $ 597.7 $ 666.6 $ 714.8 $ 651.9 $ 778.0 $ 873.8 $ 947.0 $ 2,065.3 $ 2,522.3 $ 3,250.7 Year over yea
Slide 9: Revenue Metrics By Geography
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 FY'21 FY'22 FY'23 Revenue Metrics By Geography US Revenue (millions) $ 381.2 $ 461.5 $ 489.6 $ 517.1 $ 451.2 $ 511.0 $ 573.4 $ 606.4 $ 526.0 $ 616.6 $ 713.6 $ 769.1 $ 1,849.4 $ 2,142.0 $ 2,625.3 Year over year growth 30% 26% 23%
Slide 10: Organic Revenue
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 FY'21 FY'22 FY'23 1 Organic Revenue INT'L Revenue - Reported $ 123.8 $ 133.6 $ 160.6 $ 181.1 $ 177.6 $ 185.2 $ 196.2 $ 208.8 $ 215.5 $ 254.7 $ 261.4 $ 265.4 $ 599.1 $ 767.8 $ 997.0 Impact of Acquired Revenue and Foreign Exchange
Slide 11: Definitions
DexCom, Inc. Definitions: Amortization of intangible assets - We are required by GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful lives. We exclude these non-cash amortization charges related to acquired intangible assets